Medline enters the analysis with 23% upside to the analyst price target and a 3.3-to-1 favorable risk/reward — supported by consecutive earnings beats and a near-perfect Piotroski financial-health score — but heavy reliance on three group-purchasing organizations for approximately 69% of revenues remains the central concentration risk.
Thesis pillars
- Gpo Customer Concentration Risk↓Deteriorating
- Material Upside Favorable Risk Reward→Stable
- Early Earnings Beat Consistency↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Medline Inc. (MDLN) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Sell if holding. At $36.57, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 9.3%; Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%).
Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals, surgery centers, physician offices, and post-acute facilities globally.... Read more
Sell if holding. At $36.57, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 9.3%; Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%). Chart setup: Death cross but MACD improving, RSI 71. Score 5.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 20d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: moderate.
Recent developments
updated 2026-10-16Recent Developments — Medline Inc.
Latest news
- NEWS Kaplan Fox Initiates Securities Probe into Medline Inc. After FDA Issues Warning on Manufacturing Violations - Kalkine M — Kalkine Media negative
- NEWS Readystate Asset Management LP Invests $10.74 Million in Medline $MDLN - MarketBeat — MarketBeat neutral
- NEWS Medline (MDLN) Q2 2026 Results: Profit Per Share Clears Its Benchmark in Latest Trading - vinanet.vn — vinanet.vn positive
- NEWS Tigress Financial raises Medline stock price target on AI supply chain shift By Investing.com - Investing.com South Afri — Investing.com South Africa positive
- NEWS Tigress Financial raises Medline stock price target on AI supply chain shift - Investing.com Canada — Investing.com Canada positive
Generated 2026-10-16T11:42:17Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerVizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs)69%10-K Item 1A: 'approximately $19.7 billion (or 69% of consolidated net sales ... contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.'
- LOWCustomertop five U.S. customers11%10-K Item 1A: 'our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $36.57, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 9.3%; Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%). Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $34.57. Score 5.6/10, moderate confidence.
Take-profit target: $39.98 (+9.3% upside). Prior stop was $34.57. Stop-loss: $34.57.
Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%); Thin upside margin: 9.3%; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Medline Inc. trades at a P/E of 89.8 (forward 22.8). TrendMatrix value score: 5.7/10. Verdict: Sell.
34 analysts cover MDLN with a consensus score of 4.1/5. Average price target: $44.
What does Medline Inc. do?Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately...
Medline, founded in 1966, is the largest provider of med-surg products by total net sales, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals, surgery centers, physician offices, and post-acute facilities globally. Prime Vendor agreements generated $18.0 billion (63.4% of net sales) in 2025; the company operates 70 global distribution centers and 2,100+ owned MedTrans trucks, employing over 45,000 people.